Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) -

Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
Information type: Other primary research
Source: Diabetes Care
Specialities: Cancers | Diabetes | Endocrine system disorders
Summary
Analysis of 65 patients from the EXSCEL study concludes regular calcitonin monitoring identified no additional cases of medullary thyroid cancer, highlighting no benefit of routine calcitonin monitoring during exenatide treatment.
UKMi comment
Because previous reports have suggested increases in serum calcitonin (tumour marker for medullary thyroid carcinoma (MTC)) have been associated with glucagon-like peptide 1 receptor agonist use, this study evaluated calcitonin changes in exenatide-treated patients and MTC incidence.
Related links: